BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Religare maintains buy on Aurobindo Pharma
Aurobindo's topline grew 10.4 per cent year-on-year to Rs 3,490 crore on robust US sales led by ramp-up in recent launches. However, net profit was below expectation due to lower other income. Revise FY17/FY18 revenue estimates by 5.5 and 4.4 per cent respectively building in lower sales and slow European Union business recovery.